Shoulder pain drug trial halted early
NCT ID NCT05758415
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tested whether secukinumab, an injected drug, could reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy (shoulder tendon pain). About 60 people were planned to receive either the drug or a placebo for 24 weeks. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROTATOR CUFF TENDINOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Conquest Research
Winter Park, Florida, 32789, United States
-
Horizon Clinical Research
La Mesa, California, 91942, United States
-
LV Research
Las Vegas, Nevada, 89119, United States
-
Medvin Clinical Research
Van Nuys, California, 91405, United States
-
Novartis Investigative Site
Wuhan, CHN, 430033, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050051, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Xian, Shanxi, 710004, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Shanghai, 200040, China
-
Novartis Investigative Site
Milan, MI, 20157, Italy
-
Novartis Investigative Site
Siena, SI, 53100, Italy
-
Novartis Investigative Site
Krakow, 31-141, Poland
-
Novartis Investigative Site
Swidnica, 85-100, Poland
-
Novartis Investigative Site
Torun, 87-100, Poland
-
Novartis Investigative Site
Warsaw, 00-874, Poland
-
Novartis Investigative Site
Warsaw, 02-677, Poland
-
Novartis Investigative Site
Santiago, A Coruna, 15705, Spain
-
Novartis Investigative Site
Sabadell, Barcelona, 08208, Spain
-
Novartis Investigative Site
A Coruña, 15006, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Valencia, 46024, Spain
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Chiang Mai, 50200, Thailand
Conditions
Explore the condition pages connected to this study.